ImClone Systems and Bristol-Myers Squibb said yesterday that they would begin to provide their cancer drug, Erbitux, to a limited number of colorectal cancer patients who have exhausted other treatment options.
The companies have been under pressure from cancer patients and their advocates, who have criticized the companies for not doing enough to help desperately ill people.
